Yarden / Elkabets Resistance to Anti-Cancer Therapeutics Targeting Receptor Tyrosine Kinases and Downstream Pathways

1. Auflage 2018
ISBN: 978-3-319-67932-7
Verlag: Springer International Publishing
Format: PDF
Kopierschutz: 1 - PDF Watermark

E-Book, Englisch, Band 15, 242 Seiten, eBook

Reihe: Resistance to Targeted Anti-Cancer Therapeutics

This volume comprehensively covers the multiplicity and diversity of mechanisms underlying patient resistance to currently approved anti-cancer drugs, including tyrosine kinase inhibitors and monoclonal antibodies, blockers of growth factor receptors and their downstream pathways, which play essential functions in cancer progression. Each chapter will cover a specific group of targets and the cognate drugs, along with molecular modes of innate and evolving resistance.

Zielgruppe

Research

Autoren/Hrsg.

Yarden, Yosef

Elkabets, Moshe

Inhaltsverzeichnis

Resistance of colorectal tumors to anti-EGFR antibodies.- Resistance of lung cancer to kinase inhibitors specific to EGFR or ALK.- Mechanisms of action and resistance of trastuzumab in breast cancer.- Mechanisms of resistance to molecular therapies targeting the HGF/MET axis.- RAF, MEK and ERK inhibitors as anti-cancer drugs: intrinsic and acquired resistance as a major therapeutic challenge.- Mechanisms of resistance to PI3K and AKT inhibitors.- Sensitivity and resistance to BH3 mimetics in cancer therapy.- Resistance mechanisms to cyclin-dependent kinase inhibitors.- Resistance to inhibitors of angiogenesis.

Über Autor(innen)

Yosef Yarden, PhD, is Professor, Department of Biological Regulation, The Weizmann Institute of Science, Israel.